Statins May Slow the Effects of Alzheimer's Disease According to New Study; Nymox (NASDAQ: NYMX) Has Global Patent Rights for Statin Drugs for the Treatment and Prevention of Alzheimer's Disease.HASBROUCK HEIGHTS, N.J. -- Cholesterol-lowering drugs like statins Statins A class of drugs commonly used to lower LDL cholesterol levels. Mentioned in: C-Reactive Protein were found to slow the progression of Alzheimer's disease Alzheimer's disease (ăls`hī'mərz, ôls–), degenerative disease of nerve cells in the cerebral cortex that leads to atrophy of the brain and senile dementia. (AD) in a new three year study of 342 AD patients (J. Neurol. Neurosurg. Psychiatry December, 2005; 76:1624-1629). Researchers at the University of Lille Lille, a city in France, has three public universities:
Cholesterol is a fatty substance found in animal tissue and is an important component to the human body. It is manufactured in the liver and carried throughout the body in the bloodstream. levels and to AD patients with normal cholesterol. They found that the use of cholesterol-lowering medication significantly slowed the cognitive decline that is the hallmark of AD as compared to both the unmedicated high cholesterol group and the normal cholesterol group. Nymox Pharmaceutical Corporation (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : NYMX NYMX New York Mercantile Exchange ) holds U.S. and global patent rights for the use of statin drugs for the prevention and treatment of AD. Statins are a class of cholesterol-lowering drugs that are the biggest-selling prescription pills in pharmaceutical history with estimated 2004 global sales of up to $26 billion. Alzheimer's disease is the leading cause of dementia in the elderly, afflicting af·flict tr.v. af·flict·ed, af·flict·ing, af·flicts To inflict grievous physical or mental suffering on. [Middle English afflighten, from afflight, an estimated 4.5 million people in the U.S. alone. The potential use of statins to treat Alzheimer's disease (AD) has been widely reported in the peer-reviewed medical literature, both in terms of clinical data, (such as The Lancet Neurology (Sept. 2005; 4:521-2), Arch Neurol. (July 2005; 62:1047-51 Neurology (May, 2005; 64:1531-8); Arch Neurol. (May 2005; 62:753-7); J Neurol Sci. (Mar, 2005; 229-230:147-50); Arch Gen Psychiatry (Feb. 2005; 62:217-24)) and possible mechanisms through which statins may prevent or slow the progression of Alzheimer's disease (such as J Neurosci Res (2005; 82:10-19), J Biol Chem (Aug 2005; M505268200), PLoS Med. (Jan. 2005; 2:e18); J Neurosci. (Jan. 2005; 25:299-307)) More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669. This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities. |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion